Clinical Trials Browser

Phase 2 × Hematologic Diseases × venetoclax × Clear all

NCT04062266 2026-01-13

AZA + Venetoclax as Maintenance Therapy in Patients With AML in Remission

Phase 2 Active not recruiting

Other hematologic neoplasm

Hematologic Diseases, Leukemia, Myeloid, Acute